Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab for Migraine with Medication Overuse Headache (Sunlight)
NCT04772742Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Feb 2021
- Primary completion
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 3 trial of eptinezumab in migraine, medication overuse headache (MOH), sponsored by Lundbeck. Started Feb 2021; status: completed.
02
Drugs
eptinezumab
03
Conditions
migrainemedication overuse headache (MOH)
Beyond the preview
Go deeper on NCT04772742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04772742.